Pediatric Nephrology

, Volume 24, Issue 4, pp 845–849 | Cite as

Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study

  • Koichi Nakanishi
  • Kazumoto Iijima
  • Kenji Ishikura
  • Hiroshi Hataya
  • Midori Awazu
  • Mayumi Sako
  • Masataka Honda
  • Norishige Yoshikawa
  • for the Japanese Pediatric IgA Nephropathy Treatment Study Group
Brief Report

Abstract

Even in children with mild immunoglobulin (Ig)A nephropathy (IgA-N) showing minimal/focal mesangial proliferation, persistent proteinuria seems to be a risk factor for progression of the disease, indicating the need for an effective and safe treatment even in such cases. Studies carried out to date have indicated that angiotensin-converting enzyme inhibitors (ACEIs) reduce urinary protein excretion and preserve renal function in adult IgA-N. However, no prospective study of ACEI only for childhood IgA-N has yet been carried out. In this prospective single-arm pilot trial, we administered lisinopril (0.4 mg/kg per day) as therapeutic treatment to 40 children with mild IgA-N with proteinuria [morning urinary protein/creatinine ratio (uP/Cr) ≥ 0.2 g/g]. Thirty-three patients reached the primary endpoint (uP/Cr < 0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by the Kaplan–Meier method was 80.9%. Mean uP excretion was reduced from 0.40 to 0.18 g/m2/day (p < 0.0001). Of the 40 patients treated, five (12.5%) showed dizziness, and four of these five needed the lisinopril dose reduced. However, lisinopril therapy was continued in all patients during the 2-year treatment period. No other side effect, such as cough, was observed. We conclude that the efficacy and safety of lisinopril is seemingly acceptable for the treatment of children with mild IgA-N.

Keywords

Angiotensin-converting enzyme inhibitor Focal mesangial proliferation Minimal change Proteinuria Renin-angiotensin system Urinary protein to creatinine ratio Urinary protein excretion 

References

  1. 1.
    Yoshikawa N, Nakanishi K (2006) Chronic nephritis in children— with emphasis on IgA nephropathy. In: Hogg R (ed) Kidney disorders in children and adolescents. Taylor & Francis, Abingdon, pp 103–115Google Scholar
  2. 2.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
  3. 3.
    The GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863CrossRefGoogle Scholar
  4. 4.
    Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364PubMedCrossRefGoogle Scholar
  5. 5.
    Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, Sasdelli M, Zuccalà A, Zucchelli P (1994) ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 9:265–269PubMedGoogle Scholar
  6. 6.
    Praga M, Gutiérrez E, González E, Morales E, Hernández E (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14:1578–1583PubMedCrossRefGoogle Scholar
  7. 7.
    Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888PubMedCrossRefGoogle Scholar
  8. 8.
    Yoshikawa N, Ito H, Yoshiara S, Nakahara C, Yoshiya K, Hasegawa O, Matsuo T (1987) Clinical course of IgA nephropathy in children. J Pediatr 110:555–560PubMedCrossRefGoogle Scholar
  9. 9.
    Churg J, Bernstein J, Glassock RJ (1995) Renal disease: classification and atlas of glomerular diseases, 2nd edn. Igaku-shoin Medical Publishers, Tokyo, pp 86–88Google Scholar
  10. 10.
    Guignard JP, Santos F (2004) Laboratory investigations. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 399–424Google Scholar
  11. 11.
    Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M, Japanese Pediatric IgA Nephropathy Treatment Study Group (1997) A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Nippon Jinzo Gakkai Shi 39:503–506PubMedGoogle Scholar
  12. 12.
    Bartosik LP, Lajoie G, Sugar L, Cattran DC (2001) Predicting progression in IgA nephropathy. Am J Kidney Dis 38:728–735PubMedCrossRefGoogle Scholar
  13. 13.
    Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18:3177–3183PubMedCrossRefGoogle Scholar
  14. 14.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC (2006) Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47:751–760PubMedCrossRefGoogle Scholar
  15. 15.
    Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, Blumer JL, Vogt BA, Lo MW, Hand E, Panebianco D, Rippley R, Shaw W, Shahinfar S (2007) A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 22:695–701PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  • Koichi Nakanishi
    • 1
  • Kazumoto Iijima
    • 2
  • Kenji Ishikura
    • 3
  • Hiroshi Hataya
    • 3
  • Midori Awazu
    • 4
  • Mayumi Sako
    • 1
  • Masataka Honda
    • 3
  • Norishige Yoshikawa
    • 1
  • for the Japanese Pediatric IgA Nephropathy Treatment Study Group
  1. 1.Department of PediatricsWakayama Medical UniversityWakayama CityJapan
  2. 2.Department of PediatricsKobe University Graduate School of MedicineKobeJapan
  3. 3.Department of Pediatric NephrologyTokyo Metropolitan Kiyose Children’s HospitalKiyose, TokyoJapan
  4. 4.Department of PediatricsKeio University School of MedicineShinjyuku, TokyoJapan

Personalised recommendations